


Date of Deposit is MAY 2, 2000

I hereby certify that this is being deposited with the United States Postal Service under 37 CFR 1.8 on the date indicated above and is addressed to the Assistant Commissioner for Patents, Box: SEQUENCE, Washington, D. C. 20231.

By:

Lois E. Miller, date



PATENT/DX0804K

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

PARHAM, et al.

Serial No.: 09/265,540

Filed: 08-MAR-1999

For: HUMAN RECEPTOR PROTEINS;
RELATED REAGENTS AND
METHODS

Examiner: F. Hamud

Art Unit: 1646

CORRECTION OF SEQUENCE
SUBMISSION

Palo Alto, California 94304-1104

30-MAY-2000

RECEIVED

JUN 06 2000

TECH CENTER 1600/2900

RECEIVED

JUN 08 2000

TECH CENTER 1600/2900

**COMPLIANCE WITH REQUIREMENTS FOR PATENT APPLICATIONS
CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE
DISCLOSURES**

Sir:

In reply to receipt of a "Notice to Comply" dated 27-APR-00 (Paper No. 6) for the above-identified application, Applicants submit: (1) a substitute paper and write-protected computer readable copy of the Sequence Listing as required under 37 CFR §1.825(d); (2) a statement under 37 CFR §1.825(d) and (3) a copy of the "Error Report." Since 27-MAY-00 falls on a Saturday, the period for a timely response is extended to the following business day which is Tuesday, 30-MAY-00 because Monday, 29-MAY-00 was a United States Patent & Trademark Office holiday.

Remarks

The enclosed sequence submission corrects the previous sequence submission by uniformly applying the PATENTIN 2.0 "new" format throughout the sequence listing. To the best of Applicants' knowledge and belief, the informational content of the sequence itself remains unchanged; only the presentation format has been changed. For example, in SEQ ID NO: 1 the numeric identifiers <220> to <223> were newly added to the sequence listing to explain the use of the nucleotide symbol "n."

Applicants enclose the submission on a write protected floppy diskette containing the substitute "Sequence Listing." The diskette complies with the requirements of 37 CFR §1.824 and is IBM PC compatible with a PC-DOS/MS-DOS operating system. If the diskette is damaged, please contact Applicants' representative and a replacement diskette will be provided. A paper readable copy of the substitute Sequence Listing on the diskette is attached hereto.

The informational content of the substitute paper and substitute computer readable copies of the sequence listing, submitted in accordance with 37 CFR §1.825(d) are believed to be the same and are believed to include no new matter since the informational content of the enclosed sequences should be the same as the informational content of the sequences submitted in priority documents.

The enclosed items are a bona fide effort to bring the present application into full compliance with the rules for sequence submissions. Applicants have invested over five extra hours of significant additional labor and care in preparing the present submission. Should there be any question regarding the sufficiency of this submission to comply with the rules for sequence submissions, Applicants respectfully request notification of any specific deficiencies and an opportunity to remedy them, under 37 CFR §1.135(c).

No fees should be due, however, if any are required, Applicants authorize the Commissioner to make any appropriate charges or credit any overpayments to DNAX Research Institute Deposit Account No. 04-1239.

Respectfully submitted,

Dated: MAY 30, 2000

By:

Gerald P. Keleher
Reg. No. 43,707

Enclosures and attachments:

One substitute write-protected diskette (CRM)
Substitute paper copy of contents of diskette
Copy of the Sequence Error Report

DNAX Research Institute
901 California Avenue
Palo Alto, California 94304-1104
TEL: (650) 852-9196
FAX: (650) 496-1200

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING
NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821-1.825 for the following reason(s):

- ☒ 1. This application clearly fails to comply with the requirements of 37 CFR 1.821-1.825. Applicant's attention is directed to these regulations, published at 114 FR 18230, May 15, 1990 and at 55 FR 18230, May 1, 1990.
- ☐ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 CFR 1.821(c).
- ☒ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e).
- ☐ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 CFR 1.822 and/or 1.823, as indicated on the attached copy of marked-up "Raw Sequence Listing."
- ☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 CFR 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 CFR 1.821(e).
- ☐ 7. Other: _____

Applicant must provide:

- ☒ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing"
- ☒ An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification
- ☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 CFR 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d)

For questions regarding compliance with these requirements, please contact:

For Rules Interpretation, call (703) 308-1123
For CRF submission help, call (703) 308-4212
For PatentIn software help, call (703) 557-0400

Please return a copy of this notice with your response.